Epidemiological studies strongly suggest a link between stress, depression, and cardiovascular diseases (CVDs); the mechanistic correlation, however, is poorly understood. A single-nucleotide polymorphism in the BDNF gene (BDNFVal66Met), associated with depression and anxiety, has been proposed as a genetic risk factor for CVD. Using a knock-in mouse carrying the BDNFVal66Met human polymorphism, which phenocopies psychiatric-related symptoms found in humans, we investigated the impact of this SNP on thrombosis.
Introduction
Epidemiological studies have shown a robust association between stress, depression, and increased morbidity and mortality in acute coronary syndrome (ACS). A recent review suggests that depression should be included among the risk factors (RFs) for adverse medical outcomes in patients with ACS. 1 The depressive status, resulting in an increased prevalence of cardiovascular RFs and in potential non-adherence to secondary prevention measures, is associated with an unhealthy behaviour, which in turn may cause an increased occurrence of adverse outcomes. 2 Neuroendocrine dysfunction and disturbances in cardiac autonomic control, endothelial dysfunction, inflammation, and enhanced platelet reactivity are among the mechanisms potentially implicated in the connection between depression and adverse cardiac events. 3 Indeed, the rupture of an atherosclerotic plaque coupled with activation of circulating platelets, leading to the occurrence of acute thrombosis, is the major cause of ACS. Several polymorphisms in genes (e.g. serotonin, cannabinoid receptor 1, glucocorticoid receptors) associated with mood disorders have also been linked to the development of coronary artery disease (CAD). 4 Recently, single-nucleotide polymorphisms (SNPs) in the brain-derived neurotrophic factor (BDNF) gene, which encodes for a neurotrophin that plays critical roles in neuronal strength and morphology and vascular development, 5, 6 have been included in this list. 7, 8 In particular, the rs6265 SNP leading to a valine to methionine substitution at position 66 in the BDNF protein (BDNFVal66Met) has been repeatedly associated with an increased susceptibility to depression and anxiety, 9 whereas association studies of this SNP with CAD led to conflicting results. 7,8,10 -12 In view of the role of acute vascular occlusion in ACS, we hypothesized an influence of the BDNFVal66Met polymorphism on thrombosis susceptibility. Taking advantage of a genetic knock-in mouse carrying the human BDNFVal66Met polymorphism, which phenocopies many of the psychiatric-related symptoms found in human carriers, 13 we have investigated the potential role of this SNP on thrombus formation.
Materials and methods
See Supplementary material online, Methods.
Results

BDNFVal66Met polymorphism affects basal depressive-like behaviour in mice
Chronic restraint stress has been shown to increase the immobilization time only in the heterozygous BDNF +/Met , but not in the WT mice. 14 Here, we showed that even in the absence of stress the immobilization time was increased in the homozygous BDNF Met/Met , compared with WT mice (see Supplementary material online, Figure S1 ), confirming that homozygous BDNF knockin mice reproduce the phenotype observed in subjects carrying this SNP. 6.65 + 0.14 fl, P , 0.01) compared with WT. Washed platelets (WPs) from BDNF Met/Met mice showed higher aggregation in response to collagen and thrombin ( Figure 1A and B and Supplementary material online, Figure S2A and B). Likewise, lower concentrations of ADP were required to elicit platelet-rich plasma aggregation of BDNF Met/Met mice compared with WT ( Figure 1C and Supplementary material online, Figure S2C ). Concomitantly, an increased binding of JON/A-PE antibody and of fibrinogen-FITC, markers of functional GPIIB/IIIa receptor, was measured in BDNF Met/Met WP exposed to different concentrations of thrombin or ADP ( Figure 1D and E). The increased binding of fibrinogen was accompanied by an increased adhesion of BDNF Met/Met platelets to fibrinogencoated surfaces ( Figure 1F and Supplementary material online, Figure  S3A ). In addition, clot retraction experiments showed increased amounts of serum extrusion in clots of BDNF Met/Met compared with WT mice ( Figure 1G ), which reflects alterations in cytoskeleton dynamics. P-selectin expression and platelet-leucocyte aggregates ( Figure 1H and I and Supplementary material online, Figure S3B ), as well as the levels of plasma thrombospondin- 
Influence of BDNFVal66Met polymorphism on coagulation
The interaction between blood cells and plasma factors in blood clotting was then analysed. Whole blood recalcification test showed similar coagulation times in the two groups of mice ( Figure 2A) , as confirmed by FII, FV, FVII, FVIII, FIX, FX, FXI, and FXII activities (see Supplementary material online, Figure S4 ). Clotting formation time was shorter in BDNF Met/Met than in WT mice ( Figure 2B ), consistent with higher levels of functional fibrinogen ( Figure 2C ) and platelet hyperreactivity ( Figure 1) . Accordingly, greater maximum clot firmness and maximum clot elasticity were observed in BDNF Met/Met mice ( Figure 2D and E). In addition, clot formation was associated with an increased TF activity of circulating microparticles (MP-TF) and leucocytes in BDNF Met/Met mice ( Figure 2F and G).
Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in plasma did not differ in the two groups, but the ratio tPA/PAI-1, which reflects the endogenous fibrinolytic activity, 15 was significantly lower in BDNF Met/Met mice ( Figure 2H -L). Figure S5 and Table S2 ). Gene Ontology (GO) term overrepresentation analysis of upregulated proteins revealed a significant enrichment in endopeptidase activity associated with response to cytokine stimulus, together with fatty acid oxidation, TCA cycle, and myosin complex (see Supplementary material online, Figure S6A ). Moreover, KEGG pathway analysis revealed that five proteins up-regulated in BDNF Met/Met mice (see Supplementary material online, Table S3 ) are involved in the complement and coagulation cascades. Conversely, GO analysis revealed that down-regulated proteins were mainly associated with the actin cytoskeleton and microtubules (see Supplementary material online, Figure S6B and Table S4) .
Aortic tissue characterization
We focused our attention on two proteins: Gelsolin, given its involvement in actin remodelling and regulation of clot firmness, 16 -18 and alpha1-antitrypsin (A1AT), a proinflammatory protein. 19 Consistent with the aorta secretome, lower amounts of Gelsolin and higher concentrations of A1AT were measured in plasma of BDNF Met/Met mice ( Figure 3A and B and Supplementary material online, Table S2 ). This was accompanied by greater interleukin-6 (IL-6) levels, higher erythrocyte sedimentation rate (ESR), and elevated numbers of circulating leucocytes, in particular monocytes and neutrophils ( Figure 3C -H). These data support the hypothesis that the BDNFVal66Met polymorphism modulates the fibrinolytic process affecting the clot structure and promotes a proinflammatory state.
We assessed whether the changes in Gelsolin abundance in secretome and plasma were paralleled by changes in tissue and cells. Unlike secretome and plasma, Gelsolin expression was higher in aortic tissue and in circulating platelets and leucocytes of BDNF Met/Met compared with WT mice ( Figure 4A-D) .
Intriguingly, expression of SorCS2, a sortilin family member engaged by BDNFMet prodomain in the regulation of morphological neuron changes, 20 and TF expression and activity were greater in Mean + SEM; *P , 0.05, **P , 0.01, ***P , 0.005 at unpaired Student's t-test. 
BDNFVal66Met polymorphism predisposes to thrombosis
Having established that in BDNF Met/Met mice platelet hyperreactivity, abnormal blood clotting, and increased expression of proteins linked to thrombosis/inflammation occur, we investigated the impact of this SNP using two experimental models of thrombosis. Carotid artery thrombus formation was induced by topical application of FeCl 3 5% in BDNF Met/Met and WT mice. Blood flow was reduced by 83% and by 48% in BDNF Met/Met and WT mice, respectively, within the 40-min observation time. In particular, the mean time to total occlusion (defined as a flow reduction .90%) was shorter in BDNF Met/Met mice ( Figure 5A and B).
The thrombotic phenotype detected in BDNF Met/Met mice was confirmed in the platelet-dependent pulmonary thromboembolism model. Thromboembolic death after intravenous collagen plus epinephrine injection occurred in 75% BDNF Met/Met (9 of 12) and 35%
WT (4 of 12) mice ( Figure 5C ). After injection of collagen/epinephrine, circulating platelet counts were lower in BDNF Met/Met mice, indicating that in vivo platelet activation and sequestration were more sustained ( Figure 5D ). In addition, a significantly greater expression of platelet-associated P-selectin and of platelet/leucocyte aggregates after injection of collagen/epinephrine was found in the whole blood of BDNF Met/Met mice ( Figure 5E-F) .
Resveratrol prevents the prothrombotic phenotype in BDNF Met/Met mice
Subsequent experiments were performed to elucidate the mechanism(s) by which the Met allele affects thrombosis, focusing on a potential role of SIRT1. 22 -24 Activation of SIRT1 by the natural dietary compound resveratrol reduced the number of circulating platelets and leucocytes by 27 and 40%, respectively, in BDNF Met/Met , without influencing cell count in WT mice (see Supplementary material online, Figure S7 ). In addition, resveratrol decreased platelet activation and rescued the procoagulant phenotype only in BDNF Met/Met mice, e.g. reducing platelet -leucocyte aggregate percentage ( Figure 6A ), plasma concentrations of TSP-1, MP-TF, and functional fibrinogen and increasing plasma Gelsolin (see Supplementary material online, Table S5 ). Treatment of mutant mice with resveratrol increased SIRT1 expression and down-regulated SorCS2, Gelsolin and TF back to the levels of WT aortae ( Figure 6B-F) . In addition, this treatment completely prevented thrombus formation in BDNF Met/Met mice ( Figure 6G ), without modifying arterial thrombosis in WT mice (see Supplementary material online, Figure S7 ).
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Inhibition of SIRT1 with sirtinol, which is known to increase arterial thrombogenicity and TF activity, 22 increased the expression of SorCS2, TF, and Gelsolin in WT mice, inducing a phenotype Figure S9 ).
Association of rs6265 with acute myocardial infarction in humans
To assess whether the BDNFVal66Met polymorphism is associated with a thrombotic state in a clinical setting, we took advantage of a retrospective study at our Centre (see Supplementary material online), which recruited patients with at least one coronary stenosis ≥70% undergoing coronary artery bypass graft. Nine hundred and seventy-nine subjects (see Supplementary material online, Table S6 ) were stratified according to the onset of the CAD: patients with (acute myocardial infarction, AMI; n ¼ 286) or without (stable or unstable angina; n ¼ 693) overt signs of an acute coronary thrombotic event. Genotyping of BDNF rs6265 identified 59 A/A homozygotes, 326 G/A heterozygotes, and 594 G/G homozygotes, resulting in a minor allele (A) frequency of 23%, consistent with data reported in Caucasians. 25 Association analysis revealed that BDNF rs6265 was significantly associated with AMI in the genotypic (x 2 ¼ 7.783, df ¼ 2, P ¼ 0.0204) and recessive (x 2 ¼ 5.258, df ¼ 1, P ¼ 0.0219) models, e.g. the homozygosity AA was significantly more frequent in patients with an overt thrombotic event at CAD onset than in other CAD patients (see Supplementary material online, Table S7 ). Notably, the sample size of n ¼ 979 achieved 71% power to deem as significant the observed genotypic effect size (see Supplementary material online, Table S7 ). Consistently, logistic regression analysis showed a significant association of the minor allele A with an AMI onset of CAD in our patients, with an odds ratio [95% confidence interval] of 1.857 [1.086 -3.173] (P ¼ 0.0236), assuming a recessive genetic effect. This was true also when the analysis was corrected both for age and sex (P ¼ 0.0257), and for age, sex, and major vascular RFs (P ¼ 0.0334; Table 1 ).
Discussion
The relationship between depression and ACS has been amply debated, but the physiological and behavioural underpinnings of this association remain poorly understood. Our study indicates that the substitution at codon 66 of valine with methionine in the BDNF prodomain promotes a concomitant depressive and prothrombotic/proinflammatory phenotype in mice. Platelet activation, alterations in coagulation pathways, and changes in vessel wall protein expression are all events that occur in both BDNF Met/Met mice and patients with anxiety/depression. Further, we showed that Met homozygosity is associated with AMI in a cohort of patients with severe CAD.Increased GPIb, P-selectin, and b-thromboglobulin expression, greater platelet -leucocyte interactions, and higher levels of A1AT, TSP-1, and functional fibrinogen, all contributing to ACS risk, 26 have been previously reported in patients with depression. 19,27 -29 Likewise, lower levels of SIRT1 in different tissues/cells, including circulating leucocytes, have been linked to inflammatory processes, 30 and thrombosis through modulation of TF expression and activity, 22, 23 and have been reported in patients with depression or ACS. 19,29 -31 Of note, the associations between SIRT1 SNPs and CAD, mood disorders or inflammation have been recently reported.
-34
The increased amount of TF associated with MPs, circulating leucocytes and carotid arteries, besides platelet activation, well explains the increased propensity to thrombosis observed in BDNF Met/Met mice exposed to FeCl 3 . 35 A critical role for BDNF Met/Met platelets in the worsening of thrombosis occurrence is also suggested by the pulmonary thromboembolism model. Available data, however, do not allow us to discriminate the role of vessel wall procoagulant activity vs. the prothrombotic phenotype of circulating platelets in the occurrence of thrombus formation, with either experimental model used. The role of intrinsic vascular changes is further supported by the observation that tPA/PAI-1 ratio is decreased in BDNF Met/Met mice, which may result in reduced fibrinolysis. 15 The tPA-PAI-1 imbalance is known to play an important role in the pathophysiology of mental and thromboembolic disorders. 36, 37 tPA facilitates clot dissolution and participates in several brain functions, including the response to stress, learning, and memory. 38 An alteration in the fibrinolytic process is also supported by the evidence of modification in the Gelsolin levels detected in BDNF Met/Met mice. Gelsolin in plasma is known to clear F-actin from the circulation, supporting the lytic action of plasmin; 16, 17 its cytoplasmic isoform controls several cellular processes, including platelet formation and activation. 18, 39 Lower amounts of Gelsolin were previously observed in plasma of rats with myocardial ischaemia and in patients with myocardial infarction. 40, 41 In particular, the lack of F-actin removal, consequent to reductions in circulating levels of Gelsolin, may favour platelet aggregation and lead to the formation of bigger thrombi less prone to lysis, which could lead to fatal thrombosis. 42 Interestingly, opposite to circulating levels, we found greater amounts of Gelsolin in platelets of BDNF Met/Met mice, which is in accordance with reported data in ischemic rats and in ACS patients, 40, 41 suggesting an alteration in protein trafficking.
In addition, activation of inflammation has been proposed as a link between depression and heart disease: specifically, an increase in proinflammatory cytokines, e.g. IL-6, results in a prothrombotic phenotype with endothelial perturbation and activation of circulating platelets. 4 Consistent with this hypothesis, the BDNF Logistic Regression Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, body mass index, diabetes, dyslipidemia, hypertension, and smoking habit; TEST, code for the test assuming a recessive effect; NMISS, number of non-missing patients included in analysis; for 10 patients one covariate (BMI) was unknown; OR, odds ratio; STAT, coefficient of t-statistics; P, asymptotic P-value for t-statistics.
material online, Figure S10 ) supporting the potential protective effects of SIRT1 in atherothrombosis. 31 However, the use of nonselective SIRT1 activator may represent a limitation of in vivo study. These findings are consistent with the reported involvement of BDNFMet genotype in the predisposition to CAD associated with depression. 7, 8 In contrast, data concerning the impact of BDNFVal66Met polymorphism in CAD patients without depressive disorders are conflicting: indeed, protection against unstable angina and/or no effect of this genotype were reported. 10 -12 Based on the evidence that the BDNFVal66Met polymorphism is linked to the occurrence of acute thrombosis in mice, we genotyped patients with severe CAD previously enrolled at our Centre, to look for the prevalence of the Met allele in patients presenting with an overt, acute coronary thrombotic event. Remarkably, Met homozygosity was significantly associated with AMI, independently of age, sex and major cardiovascular RFs. The main limitations of this study include its retrospective design, single-centre site, and inadequate power: thus, it needs to be confirmed in appropriately designed prospective studies. Nevertheless, these data provide support for a contribution of this BDNF polymorphism in the individual propensity for arterial thrombosis related to the occurrence of AMI.
Deciphering the role of BDNFVal66Met-related pathway in thrombosis might point out new tailored approaches for the prevention of the cardiovascular risk. Studies elucidating the mechanistic link between depression and ACS will possibly pave the way for designing single-targeted drugs with beneficial effects on both mood and cardiovascular disorders.
